SG11201603482RA - Rna transcription vector and uses thereof - Google Patents
Rna transcription vector and uses thereofInfo
- Publication number
- SG11201603482RA SG11201603482RA SG11201603482RA SG11201603482RA SG11201603482RA SG 11201603482R A SG11201603482R A SG 11201603482RA SG 11201603482R A SG11201603482R A SG 11201603482RA SG 11201603482R A SG11201603482R A SG 11201603482RA SG 11201603482R A SG11201603482R A SG 11201603482RA
- Authority
- SG
- Singapore
- Prior art keywords
- rna transcription
- transcription vector
- vector
- rna
- transcription
- Prior art date
Links
- 230000035897 transcription Effects 0.000 title 1
- 238000013518 transcription Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
- C12N2320/52—Methods for regulating/modulating their activity modulating the physical stability, e.g. GC-content
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/10—Vectors comprising a non-peptidic targeting moiety
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/10—Vectors comprising a special translation-regulating system regulates levels of translation
- C12N2840/105—Vectors comprising a special translation-regulating system regulates levels of translation enhancing translation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Pulmonology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13192555 | 2013-11-12 | ||
| PCT/EP2014/074349 WO2015071295A1 (en) | 2013-11-12 | 2014-11-12 | Rna transcription vector and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201603482RA true SG11201603482RA (en) | 2016-05-30 |
Family
ID=49578161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201603482RA SG11201603482RA (en) | 2013-11-12 | 2014-11-12 | Rna transcription vector and uses thereof |
Country Status (19)
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9950282B2 (en) | 2012-03-15 | 2018-04-24 | Flodesign Sonics, Inc. | Electronic configuration and control for acoustic standing wave generation |
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US9458450B2 (en) | 2012-03-15 | 2016-10-04 | Flodesign Sonics, Inc. | Acoustophoretic separation technology using multi-dimensional standing waves |
| US10967298B2 (en) | 2012-03-15 | 2021-04-06 | Flodesign Sonics, Inc. | Driver and control for variable impedence load |
| US9725710B2 (en) | 2014-01-08 | 2017-08-08 | Flodesign Sonics, Inc. | Acoustophoresis device with dual acoustophoretic chamber |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US11021699B2 (en) | 2015-04-29 | 2021-06-01 | FioDesign Sonics, Inc. | Separation using angled acoustic waves |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11459540B2 (en) | 2015-07-28 | 2022-10-04 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| US11474085B2 (en) | 2015-07-28 | 2022-10-18 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| US20230167456A2 (en) | 2015-08-10 | 2023-06-01 | CureVac Manufacturing GmbH | Method of increasing the replication of a circular dna molecule |
| US11085035B2 (en) | 2016-05-03 | 2021-08-10 | Flodesign Sonics, Inc. | Therapeutic cell washing, concentration, and separation utilizing acoustophoresis |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| CA3041517A1 (en) | 2016-10-19 | 2018-04-26 | Flodesign Sonics, Inc. | Affinity cell extraction by acoustics |
| CA3085784A1 (en) | 2017-12-14 | 2019-06-20 | Flodesign Sonics, Inc. | Acoustic transducer driver and controller |
| SG11202107203UA (en) | 2019-01-04 | 2021-07-29 | Etherna Immunotherapies Nv | Mrna vaccine |
| AU2020234026A1 (en) * | 2019-03-13 | 2021-11-04 | Etherna Immunotherapies Nv | mRNA vaccine |
| WO2020216911A1 (en) | 2019-04-26 | 2020-10-29 | Etherna Immunotherapies Nv | Mrna formulation |
| EP3990008A1 (en) | 2019-06-27 | 2022-05-04 | eTheRNA Immunotherapies NV | Combination therapy |
| CN115697298A (zh) | 2020-01-21 | 2023-02-03 | 伊泽阿恩埃免疫疗法股份有限公司 | 脂质纳米颗粒 |
| BR112022015666A2 (pt) | 2020-02-14 | 2022-09-27 | Etherna Immunotherapies Nv | Vacinas intranasais de mrna |
| JP2023545886A (ja) | 2020-06-11 | 2023-11-01 | イーザアールエヌーエー イムノセラピーズ エンヴェー | 脂質ナノ粒子 |
| WO2023146230A1 (ko) * | 2022-01-27 | 2023-08-03 | 에스케이바이오사이언스 주식회사 | 단백질 발현을 위한 mrna와 이를 위한 주형 |
| KR102669481B1 (ko) | 2022-03-15 | 2024-05-28 | 주식회사 협일공조 | 필터교체가 용이한 디퓨저 |
| KR102624969B1 (ko) * | 2023-04-03 | 2024-01-16 | 한국과학기술원 | mRNA 번역 증가를 유도하는 mRNA 3'UTR 서열 |
| KR20250008698A (ko) * | 2023-07-07 | 2025-01-15 | 에스케이바이오사이언스(주) | 단백질 발현을 위한 rna 및 이를 위한 주형 |
| CN119876127A (zh) * | 2023-10-23 | 2025-04-25 | 康希诺(上海)生物研发有限公司 | 一种用于体外转录mRNA的质粒载体、构建方法及其应用 |
| WO2025133179A1 (en) | 2023-12-22 | 2025-06-26 | Etherna Immunotherapies Nv | Lipid nanoparticles |
| WO2025133197A2 (en) | 2023-12-22 | 2025-06-26 | Etherna Immunotherapies Nv | Polynucleotides comprising 5'utr - 3' utr combinations and use thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IS2334B (is) | 1992-09-08 | 2008-02-15 | Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) | Aspartyl próteasi hemjari af nýjum flokki súlfonamíða |
| US6043358A (en) | 1995-11-01 | 2000-03-28 | Merck & Co., Inc. | Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases |
| US5861240A (en) * | 1996-02-28 | 1999-01-19 | The Regents Of The University Of California | Isolated human herpesvirus type 8 sequences and uses thereof |
| GB9718913D0 (en) | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
| US6369087B1 (en) | 1999-08-26 | 2002-04-09 | Robert R. Whittle | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
| CA2398541A1 (en) * | 2000-01-28 | 2001-08-02 | The Scripps Research Institute | Synthetic internal ribosome entry sites and methods of identifying same |
| US7468275B2 (en) * | 2000-01-28 | 2008-12-23 | The Scripps Research Institute | Synthetic internal ribosome entry sites and methods of identifying same |
| US7608699B2 (en) * | 2003-12-29 | 2009-10-27 | Rockefeller University | Synthetic nuclear localization signal derived from lentiviral integrase and methods of use thereof |
| DE602005012085D1 (de) * | 2004-06-04 | 2009-02-12 | Centre Nat Rech Scient | Wirkstoffe zur vorbeugung oder behandlung von immunschwäche, autoimmunerkrankungen oder für die induktion von immuntoleranz |
| JP4964493B2 (ja) * | 2006-04-28 | 2012-06-27 | 株式会社カネカ | 内部リボソーム結合部位を利用した遺伝子組換え全抗体の効率的生産法 |
| ES2573458T3 (es) * | 2007-09-14 | 2016-06-08 | Vrije Universiteit Brussel | Mejoramiento de la capacidad estimulatoria de las células T de las células que presentan antígeno humano y su uso en vacunación |
| CN103911378A (zh) * | 2007-12-11 | 2014-07-09 | 斯克利普斯研究所 | 涉及mRNA翻译增强因子的组合物和方法 |
| BRPI0907501B1 (pt) * | 2008-02-01 | 2021-02-23 | Ceres, Inc | construto de vetor, método para dirigir a transcrição, método de expressão de uma região de codificação exógena, método de alteração da expressão de um gene e método de produção de uma planta transgênica |
-
2014
- 2014-11-12 NO NO14799996A patent/NO3068888T3/no unknown
- 2014-11-12 PT PT181531336T patent/PT3336192T/pt unknown
- 2014-11-12 JP JP2016530224A patent/JP6530393B2/ja active Active
- 2014-11-12 MX MX2016006134A patent/MX2016006134A/es active IP Right Grant
- 2014-11-12 EA EA201690965A patent/EA035313B1/ru unknown
- 2014-11-12 CA CA2929203A patent/CA2929203C/en active Active
- 2014-11-12 EP EP14799996.5A patent/EP3068888B1/en active Active
- 2014-11-12 PT PT147999965T patent/PT3068888T/pt unknown
- 2014-11-12 WO PCT/EP2014/074349 patent/WO2015071295A1/en active Application Filing
- 2014-11-12 DK DK14799996.5T patent/DK3068888T3/en active
- 2014-11-12 EP EP18153133.6A patent/EP3336192B1/en active Active
- 2014-11-12 CN CN202010547507.4A patent/CN111621524A/zh active Pending
- 2014-11-12 HU HUE18153133A patent/HUE058792T2/hu unknown
- 2014-11-12 SG SG11201603482RA patent/SG11201603482RA/en unknown
- 2014-11-12 ES ES18153133T patent/ES2908268T3/es active Active
- 2014-11-12 PL PL14799996T patent/PL3068888T3/pl unknown
- 2014-11-12 CN CN201480071159.0A patent/CN105849269B/zh active Active
- 2014-11-12 PL PL18153133T patent/PL3336192T3/pl unknown
- 2014-11-12 US US15/034,048 patent/US10159755B2/en active Active
- 2014-11-12 ES ES14799996.5T patent/ES2666380T3/es active Active
- 2014-11-12 CA CA3191243A patent/CA3191243A1/en active Pending
- 2014-11-12 HU HUE14799996A patent/HUE038831T2/hu unknown
- 2014-11-12 NZ NZ720885A patent/NZ720885A/en unknown
- 2014-11-12 KR KR1020167015562A patent/KR102267412B1/ko active Active
- 2014-11-12 AU AU2014350222A patent/AU2014350222B2/en active Active
- 2014-11-12 KR KR1020217018401A patent/KR102396589B1/ko active Active
- 2014-11-12 DK DK18153133.6T patent/DK3336192T3/da active
-
2016
- 2016-05-10 IL IL24559616A patent/IL245596B/en active IP Right Grant
-
2018
- 2018-08-21 US US16/106,912 patent/US10864284B2/en active Active
-
2019
- 2019-05-16 JP JP2019092623A patent/JP6900054B2/ja active Active
-
2020
- 2020-11-13 US US17/097,815 patent/US20210060182A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL245596B (en) | A vector for rna transcription and its uses | |
| IL269461B (en) | Cytidine-5-carboxamide modified nucleotide preparations and related methods | |
| GB2535911B (en) | Strigolactone formulations and uses thereof | |
| IL243899B (en) | Garp-binding proteins and their uses | |
| GB201317889D0 (en) | Product and use | |
| IL245839A0 (en) | Inhibitors of rna polymerase i and use of preparations containing them for treatment | |
| EP2988742A4 (en) | THIAZOLES AND USES THEREOF | |
| EP3048538A4 (en) | Vector operation core and vector processor | |
| PL2964767T3 (pl) | Geny kodujące toksyny i sposoby ich zastosowania | |
| IL240248A0 (en) | Met-binding substances and their uses | |
| GB201310350D0 (en) | Curable compositions and membranes | |
| AP2016009207A0 (en) | Genetic markers and uses therefor | |
| SG11201600235TA (en) | Castings and manufacture methods | |
| EP2964610A4 (en) | VINYL SULFON-BASED 18F LABELING COMPOSITIONS AND METHOD AND USES THEREOF | |
| GB201309178D0 (en) | Enzyme and uses thereof | |
| GB201320992D0 (en) | Complex and uses thereof | |
| ZA201601880B (en) | Hetero-transglycosylase and uses thereof | |
| WO2014202624A9 (en) | Rasamsonia gene and use thereof | |
| GB201305297D0 (en) | Novel agents and uses thereof | |
| GB201304585D0 (en) | Methods and product | |
| GB201301393D0 (en) | Kiddibidet and pottibidet | |
| GB201304166D0 (en) | CelebQuiff and Instant Quiff | |
| GB201318949D0 (en) | Genes | |
| GB201309328D0 (en) | Product and use thereof | |
| GB201306435D0 (en) | Vector |